Relay Therapeutics Inc. (NASDAQ:RLAY) finished Friday with a subtraction of -$0.19 to close at $10.73, a downside of -1.74 percent. An average of 1,146,780 shares of common stock have been traded in the last five days. There was a fall of -$0.52 in the past week, and it reached a new high 7 times over the past 12 months. The last 20 days have seen an average of 901,255 shares traded, while the 50-day average volume stands at 1,121,062.
RLAY stock has decreased by -15.38% in the last month. The company shares reached their 1-month lowest point of $10.21 on 08/07/23. With the stock rallying to its 52-week high on 02/02/23, shares of the company touched a low of $9.67 and a high of $33.06 in 52 weeks. It has reached a new high 9 times so far this year and lost -28.18% or -$4.21 in price. In spite of this, the price is down -67.54% from the 52-week high.
Insider Transactions
RLAY stock investors should be aware that Relay Therapeutics Inc. (RLAY) stock had its last reported insider trading activity 15 days ago on Jul 28. In this transaction, the insider spent $31,659. Chief Financial Officer, Catinazzo Thomas, disposed of 1,693 shares at a price of $11.80 on Jul 28. The insider now owns more than $19,977 worth of shares. Prior to that, Chief Legal Officer Adams Brian went on to Sale 1,628 shares at $11.80 each on Jul 28. An amount of $19,210 was transacted.
Valuation Metrics
Relay Therapeutics Inc. (RLAY) stock’s beta is 1.36. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 1068.08, the price-to-book (PB) ratio at 1.47.
Financial Health
The quick ratio of Relay Therapeutics Inc. for the three months ended June 29 was 13.60, and the current ratio was 13.60, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Relay Therapeutics Inc.’s EBITDA margin for the year ending June 29 is -22217.38%. Its gross profit as reported stood at $300.66 million compared to revenue of $1.38 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Relay Therapeutics Inc.’s return on assets was -30.80%.
Earnings Surprise
In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$98.51 million in the quarter, while revenues of -$94.24 million were grew 22.05%. The analyst consensus anticipated Relay Therapeutics Inc.’s latest quarter earnings to come in at -$0.82 per share, but it turned out to be -$0.81, a 1.20% surprise. For the quarter, EBITDA amounted to -$106.92 million. Shareholders own equity worth $122.13 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Relay Therapeutics Inc. (RLAY) price momentum. RSI 9-day as of the close on 11 August was 38.31%, suggesting the stock is Neutral, with historical volatility in this time frame at 66.32%.
As of today, RLAY’s price is $10.87 -4.62% or -$0.52 from its 5-day moving average. RLAY is currently trading -12.26% lower than its 20-day SMA and -31.35% lower than its 100-day SMA. However, the stock’s current price level is -3.68% below the SMA50 and -46.88% below the SMA200.
The stochastic %K and %D were 30.30% and 31.79%, respectively, and the average true range (ATR) was 0.73. With the 14-day stochastic at 21.49% and the average true range at 0.71, the RSI (14) stands at 41.02%. The stock has reached -0.17 on the 9-day MACD Oscillator while the 14-day reading was at -0.53.
Analyst Ratings
Jefferies upgraded Relay Therapeutics Inc. (NASDAQ: RLAY) to a a Hold rating in its most recent analyst report. Previously, the stock was rated as an Underperform. The consensus rating for Relay Therapeutics Inc. (RLAY) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell RLAY, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 12 others rate it as a “buy”.
What is RLAY’s price target for the next 12 months?
Analysts predict a range of price targets between $15.00 and $38.00, with a median target of $29.00. Taking a look at these predictions, the average price target given by analysts for Relay Therapeutics Inc. (RLAY) stock is $27.58.
